Drug intelligence / Profile preview

kudinoside A

Development stage: Unknown
Lead developer: 上海凯屹医药科技
Modality: Small Molecules
Administration: Inhalation

Overview

Kudinoside A is a triterpenoid saponin isolated from the leaves of *Ilex kudingcha* (Kuding tea). It is being developed by Shanghai General Hospital as an inhaled therapy for the treatment of chronic obstructive pulmonary disease (COPD). The compound exhibits anti-inflammatory and antioxidant properties, which are hypothesized to mitigate airway inflammation and improve pulmonary function in COPD patients. Clinical evaluation is currently focused on safety and pulmonary function effects in adults with moderate COPD through inhaled administration of a solution formulation.

Targets

NF-κB

Beyond the preview

Go deeper on kudinoside A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on kudinoside A.

Explore the full profile